Physician profile
Aryeh Abeles
NPI 1285737155
$40,801.44
in general payments reported to CMS, 2019-2025
30 companies · $10K in 2025
The $10K reported for 2025 was more than what 90% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.11 · 2020: $7,466 · 2021: $4,702 · 2022: $12K · 2023: $2,510 · 2024: $4,057 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,997 · Consulting Fee: $7,766 · Travel and Lodging: $917 · Education: $88.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,996.83 |
| Consulting Fee | $7,765.63 |
| Travel and Lodging | $917.43 |
| Education | $88.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $15,113.67 | 2020-2025 | Tremfya |
| Abbvie INC. | $9,918.13 | 2020-2025 | Rinvoq, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $4,479.60 | 2020-2025 | Orencia, Sotyktu |
| Janssen Scientific Affairs, LLC | $2,750.00 | 2021 | |
| Ucb, INC. | $1,882.49 | 2020-2025 | Bimzelx, Cimzia |
| Amgen INC. | $1,404.01 | 2020-2025 | Evenity, Prolia, Krystexxa |
| Lilly USA, LLC | $870.98 | 2020-2025 | Taltz, Zepbound |
| Radius Health, INC. | $705.94 | 2020-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $582.53 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $552.39 | 2020-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $417.71 | 2022-2025 | Lupkynis |
| Genzyme Corporation | $332.34 | 2020-2025 | |
| Sobi, INC | $300.97 | 2019-2025 | |
| Pfizer INC. | $288.54 | 2019-2022 | |
| Genentech USA, INC. | $288.36 | 2019-2025 | Actemra, Rituxan, Gazyva |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $221.45 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.37 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $95.78 | 2023-2024 | Idacio |
| Novartis Pharmaceuticals Corporation | $83.46 | 2021-2023 | |
| Organon LLC | $79.24 | 2021-2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $45.41 | 2022 | |
| Hikma Pharmaceuticals USA | $37.50 | 2020-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $37.37 | 2023 | Arcalyst |
| Scilex Pharmaceuticals INC. | $34.61 | 2024 | |
| Ani Pharmaceuticals, INC. | $24.61 | 2024 | Purified Cortrophin Gel |
| Almatica Pharma LLC | $20.86 | 2025 | Teriparatide |
| Gilead Sciences, INC. | $20.72 | 2020 | |
| Octapharma USA, INC. | $20.70 | 2024 | Octagam Immune Globulin (Human) |
| Sandoz INC. | $17.85 | 2024 | Hyrimoz |
| Actelion Pharmaceuticals US, INC. | $16.85 | 2023 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aryeh Abeles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.